CDTTW
Conduit Pharmaceuticals Inc.Key Statistics
About Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc. (CDTTW) is an innovative biopharmaceutical firm focused on advancing groundbreaking therapies for oncology and autoimmune diseases, thereby fulfilling significant unmet medical needs in these high-demand areas. Leveraging its proprietary drug delivery technologies and a robust clinical pipeline, Conduit is committed to translating leading-edge scientific discoveries into tangible clinical solutions that significantly improve patient outcomes. The company’s strategic partnerships enhance its prospects for novel treatment developments, positioning Conduit as a notable investment opportunity within the dynamic biotech sector, particularly as it progresses through critical phases of clinical trials.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-24.74M |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -345.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-77.82 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $2.29M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently expanding